198 related articles for article (PubMed ID: 25363199)
1. Relations between mood characteristics, circadian preferences, and functionality in multiple sclerosis.
Ozdemir PG; Milanlioglu A; Boysan M; Cilingir V; Aydin N; Atli A
Int J Psychiatry Clin Pract; 2015 Jun; 19(2):148-54. PubMed ID: 25363199
[TBL] [Abstract][Full Text] [Related]
2. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
Hadjimichael O; Vollmer T; Oleen-Burkey M;
Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
[TBL] [Abstract][Full Text] [Related]
3. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
[TBL] [Abstract][Full Text] [Related]
5. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Duddy M; Palace J
Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
[No Abstract] [Full Text] [Related]
6. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
7. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
8. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Johnson BH; Bonafede MM; Watson C
CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
[TBL] [Abstract][Full Text] [Related]
9. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
10. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
11. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
12. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
[TBL] [Abstract][Full Text] [Related]
13. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
[TBL] [Abstract][Full Text] [Related]
14. Disease modifying therapies for relapsing multiple sclerosis.
Wingerchuk DM; Weinshenker BG
BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal radiosensitivity in patients with multiple sclerosis.
Milenkova M; Milanov I; Kmetska K; Deleva S; Popova L; Hadjidekova V; Groudeva V; Hadjidekova S; Domínguez I
Mutat Res; 2013 Sep; 749(1-2):3-8. PubMed ID: 23994714
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
17. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients.
Adamczyk-Sowa M; Pierzchala K; Sowa P; Polaniak R; Kukla M; Hartel M
J Physiol Pharmacol; 2014 Aug; 65(4):543-50. PubMed ID: 25179086
[TBL] [Abstract][Full Text] [Related]
18. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.
Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P
Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989
[TBL] [Abstract][Full Text] [Related]
19. [New active substances expand the treatment options for MS].
Hellwig B
Med Monatsschr Pharm; 2015 Feb; 38(2):65-8. PubMed ID: 26376542
[No Abstract] [Full Text] [Related]
20. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
Rotondi M; Bergamaschi R; Chiovato L
Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
